Several lawmakers are targeting the sky-high price of an old drug that cost just $50 for a bottle of 100 pills a little more than a decade ago but goes for $15,000 today.

The drug, which was once called Daranide and is now known as Keveyis, was originally approved in 1958 to treat glaucoma, although it was more recently approved to combat periodic paralysis and received orphan status. This means the drug was endorsed for a rare disorder affecting a small group of people — about 5,000 in the U.S. — and also several years of market exclusivity.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • One might also observe that here was a ‘local to Boston’ example – Amag Pharmaceuticals of Waltham (MA), which makes Makena. There was another in the St Louis area that I cannot recall where the FDA did step in – who can forget that one, although, sadly, I cannot recall the company name.

    • Ah, think URL (acquired by Takeda?) and Colcrys – after reapproval, the cost delta was an increase to $5/pill …. from $0.09 USD [ or 9 cents]. (Source – Pharmalot, 05 MAY 2015)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy